Zagotenemab

CAS No. 2019133-28-7

Zagotenemab( —— )

Catalog No. M36688 CAS No. 2019133-28-7

Zagotenemab is a humanized antibody against the microtubule-associated protein tau that selectively regulates tau deposits in the brain. Zagotenemab can be used to study neurological disorders such as Alzheimer's disease.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 407 In Stock
10MG 655 In Stock
25MG 998 In Stock
50MG 1321 In Stock
100MG 1758 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Zagotenemab
  • Note
    Research use only, not for human use.
  • Brief Description
    Zagotenemab is a humanized antibody against the microtubule-associated protein tau that selectively regulates tau deposits in the brain. Zagotenemab can be used to study neurological disorders such as Alzheimer's disease.
  • Description
    Zagotenemab (LY3303560) is a humanised anti-tau antibody that selectively binds and neutralises tau deposits in the brain. Zagotenemab can be used in Alzheimer's disease research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Microtubule Associated
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2019133-28-7
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Abyadeh M, et al. Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease. Aging Dis. 2021 Dec 1;12(8):1964-1976. ?
molnova catalog
related products
  • Moschamine

    Moschamine is a very potent compound that is able to inhibit COX-I by 58% and COX-II by 54%, at the concentration of 0.1 μmol L⁻1, it may suppress cAMP formation via binding to 5-HT1 receptors in the cells. Moschamine exerts antitumour effects on HeLa, MCF7 and A431 cells.

  • Geranylacetone

    Geranylacetone has trypanostatic activity and could protect animals against the T. congolense-induced anaemia through the inhibition of sialidase and/or the protection of the parasite-induced hepatosplenomegaly.

  • SCS

    SCS a potent selective inhibitor of α2β1γ1θ GABA(A) receptors with a maximum inhibition of 56+/-5% and an IC50 of 32 nM.